Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure.

Yousry Esam-Eldin Abo-AmerRehab BadawiMohamed El-AbgeegyHeba Fadl ElserganyAhmed Abdelhaleem MohamedSahar Mohamed MostafaHatem Samir AlegailyShaimaa SolimanSally ElnawasanySherief M Abd-Elsalam

Published in: Advances in virology (2020)

Retreatment of HCV genotype 4 patients with quadruple therapy is a good therapeutic option and achieves high response rates with minimal side effects.

Keyphrases

helicobacter pylori
hepatitis c virus
helicobacter pylori infection
stem cells
mesenchymal stem cells
smoking cessation